bay-k-8644 has been researched along with riluzole in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Huang, CS; Nagata, K; Narahashi, T; Song, JH; Yeh, JZ | 1 |
| Chen, S; Yaari, Y; Yue, C | 1 |
| Bieger, D; Burke, MM; Tabrizchi, R | 1 |
6 other study(ies) available for bay-k-8644 and riluzole
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Calcium Channel Blockers; Calcium Channels; Dose-Response Relationship, Drug; Ganglia, Spinal; Neuroprotective Agents; Nimodipine; Rats; Rats, Sprague-Dawley; Riluzole; Thiazoles | 1997 |
A transitional period of Ca2+-dependent spike afterdepolarization and bursting in developing rat CA1 pyramidal cells.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Action Potentials; Anesthetics, Local; Animals; Animals, Newborn; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Dendrites; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Hippocampus; Male; Organ Culture Techniques; Periodicity; Pyramidal Cells; Rats; Rats, Inbred Strains; Riluzole; Tetrodotoxin | 2005 |
Agonist-induced periodic vasomotion in rat isolated pulmonary artery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; 8-Bromo Cyclic Adenosine Monophosphate; Adrenergic alpha-1 Receptor Agonists; Animals; Benzophenanthridines; Calcium Channel Agonists; Calcium Signaling; Carbenoxolone; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Endothelium, Vascular; Gap Junctions; In Vitro Techniques; Male; Methacholine Chloride; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Phenylephrine; Pinacidil; Potassium Channels; Protein Kinase C; Protein Kinase Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Riluzole; Ryanodine; Tetraethylammonium; Vasomotor System | 2011 |